“…It is S‐phase specific and causes competitive inhibition of DNA polymerase in mitotically active cells, thus preventing DNA replication, halting the cell cycle and precipitating apoptosis (Gmeiner et al., 2003; Scott‐Moncrief et al., 1991; Withrow et al., 2012). It has therefore been used for the treatment of multiple disease processes involving pathologic cell replication, including lymphoma (involving the bone marrow or central nervous system and in cases of relapse), leukaemia and optic neuritis of non‐infectious origin (Gillem et al., 2015; Marconato et al., 2008; LaRue et al., 2018; Pawlak et al., 2014, 2016; Bedos et al., 2020; Alvarez et al., 2006). As MUE is highly suspected to be due to a robust T‐cell autoimmune response, CA has been utilized as a treatment option for meningoencephalomyelitis of unknown aetiology (MUE) with the goal of inhibiting the pathologic lymphocyte proliferation associated with this autoimmune disease (Vitale et al., 2019).…”